Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

NCT02164812 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV/AIDS

Interventions

DRUG: Moxifloxacin
DRUG: Placebo
DRUG: Efavirenz

Sponsor

Bristol-Myers Squibb